Results for tag: "Lisocabtagene Maraleucel"

Lisocabtagene Maraleucel (Liso-cel) is a chimeric antigen receptor (CAR) T-cell therapy used to treat certain types of non-Hodgkin lymphoma (NHL). It is a type of immunotherapy, which uses a patient's own immune cells to fight cancer. Liso-cel is a type of CAR T-cell therapy that is specifically designed to target the CD19 antigen, which is found on the surface of B-cells. It is approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The Liso-cel market is a rapidly growing segment of the lymphoma drugs market. It is expected to witness a strong growth rate over the forecast period, owing to the increasing prevalence of NHL and the growing demand for advanced treatments. Additionally, the increasing number of clinical trials and the availability of government funding for research and development are expected to drive the market growth. Some of the key players in the Liso-cel market include Novartis AG, Kite Pharma, Inc., Gilead Sciences, Inc., Celgene Corporation, and Juno Therapeutics, Inc. Show Less Read more